Home Icon

Loading, Please Wait...

Portola Pharmaceuticals to Webcast Presentation at Cowen and Company’s 39th Annual Health Care Conference

1212 Days ago

SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer, will present a corporate overview at Cowen and Company’s 39th Annual Health Care Conference in Boston on Tuesday, March 12, 2019 at 8:40 a.m. ET (5:40 a.m. PT).

Webcast Details
To access the live investor webcast on Tuesday, March 12, at 8:40 a.m. ET (5:40 a.m. PT), go to the investor section of the company’s website at http://investors.portola.com. A replay will be available for 30 days.

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, and Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.

Investor Contact: Media Contact:
Cara Miller Pure Communications
Portola Pharmaceuticals  Portola_Media@purecommunications.com 

We Are Diffrent
Is your business listed correctly on America’s largest city directory network of 1,000 portals? Find your City Portal